Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada... see more

Recent & Breaking News (TSX:GUD)

Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call

GlobeNewswire 4 days ago

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 9, 2024

Knight Therapeutics Inc. ranks on The Globe and Mail's fifth-annual Women Lead Here benchmark of executive gender diversity

GlobeNewswire March 28, 2024

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

GlobeNewswire March 21, 2024

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

GlobeNewswire March 14, 2024

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

GlobeNewswire February 29, 2024

Knight Therapeutics Inc. Celebrates its First Decade of Success

GlobeNewswire February 28, 2024

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

GlobeNewswire February 21, 2024

Knight Therapeutics Announces Launch of Bijuva® in Canada

GlobeNewswire February 6, 2024

Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203

GlobeNewswire January 25, 2024

Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada

GlobeNewswire January 4, 2024

Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada

GlobeNewswire December 19, 2023

Knight Therapeutics Reports Third Quarter 2023 Results

GlobeNewswire November 9, 2023

Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call

GlobeNewswire November 2, 2023

Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

GlobeNewswire October 16, 2023

Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

GlobeNewswire October 10, 2023

Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies

GlobeNewswire October 2, 2023

Knight Therapeutics Reports Second Quarter 2023 Results

GlobeNewswire August 10, 2023

Notice of Knight Therapeutics' Second Quarter 2023 Results Conference Call

GlobeNewswire August 3, 2023

Knight Announces Normal Course Issuer Bid

GlobeNewswire July 12, 2023